Skip to main content
Caplight Logo









SynuCa Therapeutics

SynuCa Therapeutics

Private
CopenhagenHealthcare & Life Scienceshttps://www.synuca.com/

Last Round

Follow-on Offering

Mar 2, 2026

Total Funding Raised

$2.01M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

SynuCa Therapeutics is a drug discovery company that develops small molecule therapies intended to address Parkinson's disease and other neurodegenerative disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

disease-modifying therapysmall molecule therapyParkinson's diseasesynucleinopathyneurodegenerative diseasecalcium modulatordrug discoverybiotech R&DSERCA targetpreclinical biotechcalcium imbalancepharma licensingfirst-in-class therapyalpha-synuclein

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SynuCa Therapeutics Comparables

Compare SynuCa Therapeutics with similar companies based on industry and business-model similarity.

SynuCa Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Teitur Trophics
71%
Mission Therapeutics
70%
Gain Therapeutics Inc
69%

SynuCa Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Follow-on OfferingMar 2, 2026
AcceleratorFeb 25, 2025

Key People

Founding team and executive leadership

Lasse Reimer

Chief Executive Officer

Executive Team

William Dalby-Brown

Chief Operating Officer, SynuCa Therapeutics ApS

Executive Team

SynuCa Therapeutics Investors

Notable investors and investment history

SynuCa Therapeutics investors
InvestorRounds
BioInnovation InstituteFollow-on Offering, Accelerator
NOMEAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 2, 2026

    $1.49M round led by BioInnovation Institute.

  • Feb 25, 2025

    $520K raised from BioInnovation Institute and NOME.

SynuCa Therapeutics Filings

Explore SEC and related filing metadata, where available.

SynuCa Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about SynuCa Therapeutics's valuation, stock price, and market status.

Is SynuCa Therapeutics a public or private company?

SynuCa Therapeutics is a private company.

What is the current stock price of SynuCa Therapeutics?

SynuCa Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is SynuCa Therapeutics worth (valuation)?

Valuation information for SynuCa Therapeutics is not publicly available.

Can I buy SynuCa Therapeutics stock?

SynuCa Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was SynuCa Therapeutics's last funding round?

Funding round information for SynuCa Therapeutics is not publicly available.

Who are the main investors in SynuCa Therapeutics?

Investor information for SynuCa Therapeutics is not publicly disclosed.

Will SynuCa Therapeutics IPO soon?

No public IPO plans have been announced for SynuCa Therapeutics.

How can I track SynuCa Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor SynuCa Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCopenhagen
Employee Range2
Year Founded2025
Last FundingMar 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?